GLPwatch
Papers (9189)
Page 148 of 154, ranked by citation count.
- Liraglutide as First-Line Therapy for Type 2 Diabetics With Post-COVID-19 Fatigue Syndrome and Executive Function Deficits.
- External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.
- Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.
- Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
- Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
- Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model.
- Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.
- Gila Monster Lizard & Incretin-mimetics.
- Letter by Ma et al Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.
- Pharmacotherapy for obesity management.
- GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.
- The effect of exenatide (GLP-1a) and sitagliptin (DPP-4i) on paraoxonase 1 (PON1) activity and expression in normal and fructose-fed rats.
- Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy.
- Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.
- Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.
- Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.
- Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.
- Exenatide challenge in oral glucose tolerance test is insufficient for predictions of glucose metabolism and insulin secretion after sleeve gastrectomy (SG) in obese patients with type 2 diabetes: a pilot study to establish a preoperative model to estimate β-cell function following augmented glucagon-like peptide-1 secretion after SG.
- Repairing effects of liraglutide on spinal cord injury in rats via PI3K/AKT/ENOS signaling pathway.
- Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents.
- [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
- Body image in the age of GLP-1s: Emerging questions for research and practice.
- [GLP1 receptor agonist drug treatments and adult obesity].
- Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.
- The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.
- Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece.
- Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis.
- [Exenatide promotes chemotactic migration of adipose-derived stem cells through SDF-1/CXCR-4/Rho GTPase pathway].
- Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.
- Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.
- [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
- Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs.
- [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
- Initium novum?
- Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.
- [Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].
- In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- 12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.
- Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.
- Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane.
- A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.
- Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
- [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].
- Exendin-4 - A potential therapeutic for type 2 diabetes-linked cervical cancer?
- Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
- [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
- Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
- Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.
- Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
- Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers.
- Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.
- Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.
- Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
- The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.
- Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
- Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.